SCHEMBL840932

SCHEMBL840932

NS(=O)(=O)c1ccc2nc3c(nc2c1)-c1cccc2cc(S(=O)(=O)O)cc-3c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.51
CYP1A2 P05177 1/20 0.45
LMNA P02545 1/20 0.40
CA1 P00915 8/20 0.38
CA2 P00918 8/20 0.38
CA12 O43570 6/20 0.38
CA9 Q16790 6/20 0.38
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
PKM P14618 2/20 0.34
RAB9A P51151 2/20 0.34
HTT P42858 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CLTC Q00610 1/20 0.34
POLB P06746 2/20 0.34
MAPT P10636 2/20 0.34
NT5E P21589 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SCD O00767 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14845574 0.95 TDP1 (0.48) TDP1CYP1A2LMNACA1CA2
SCHEMBL842390 0.91 TDP1 (0.54) TDP1CYP1A2LMNACA1CA2
SCHEMBL838123 0.87 TDP1 (0.49) TDP1CYP1A2LMNACA1MEN1
SCHEMBL840342 0.87 TDP1 (0.61) TDP1CYP1A2LMNACA1CA2
SCHEMBL840742 0.86 TDP1 (0.50) TDP1CYP1A2LMNACA1MEN1
SCHEMBL1450590 0.86 RAB9A (0.44) CYP1A2MEN1KMT2APKMRAB9A
SCHEMBL17742670 0.84 CYP1A2 (0.42) CYP1A2LMNAMEN1KMT2APKM
SCHEMBL3222486 0.84 CYP1A2 (0.57) TDP1CYP1A2LMNACA1CA2
SCHEMBL14541678 0.84 MAPT (0.52) TDP1CYP1A2LMNAMEN1KMT2A
SCHEMBL824403 0.83 RAB9A (0.43) CYP1A2LMNAMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8416376-B2 Compensated in-plane switching mode liquid crystal display CRYSOPTIX KK (JP) 2013-04-09 US disclosed
US-8142863-B2 Color liquid crystal display and compensation panel Crysoptix, KK (JP) 2012-03-27 US disclosed
US-7889297-B2 Liquid crystal display operating in a vertically aligned mode Crysoptix, KK (JP) 2011-02-15 US disclosed
US-20100149471-A1 Compensated In-Plane Switching Mode Liquid Crystal Display CRYSOPTIX KK (JP) 2010-06-17 US disclosed
US-20100118241-A1 Liquid Crystal Display Operating in a Vertically Aligned Mode CRYSOPTIX KK (JP) 2010-05-13 US disclosed
US-20090268136-A1 Color Liquid Crystal Display and Compensation Panel CRYSOPTIX KK (JP) 2009-10-29 US disclosed
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof CRYSOPTIX K.K. (JP) 2009-07-30 US disclosed
US-20090161037-A1 Backlight Module and Liquid Crystal Display Incorporating the Same CRYSOPTIX KK (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof HCN3, CFH, KCNH1 TDP1 4786/4885CYP1A2 1745/4885LMNA 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.